UK’s Rising Rebate Threatens Branded Generic And Biosimilar Supply

The British Generic Manufacturers Association has made a renewed call for UK government action over a rebate scheme that threatens the supply of branded generics and biosimilars, warning that shortages and market withdrawals are inevitable if measures are not taken to address the skyrocketing rebate rate in 2023.

The Voluntary Scheme for Branded Medicines Pricing and Access, or VPAS, was introduced in 2019 and aims to balance innovation and patient access, as well as ensure predictability on National Health Service spending for branded medicines, by